Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2740966> ?p ?o }
Showing triples 1 to 45 of
45
with 100 triples per page.
- Q2740966 subject Q7116685.
- Q2740966 subject Q8549960.
- Q2740966 subject Q8561985.
- Q2740966 subject Q8919936.
- Q2740966 subject Q9052323.
- Q2740966 abstract "Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On September 24, 2014 the FDA approved Elvitegravir (tradename Vitekta) as a single pill formulation. On November 5, 2015 the FDA approved the drug for use in patients affected with HIV-1 as a part of a second fixed dose combination pill known as Genvoya.According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.".
- Q2740966 atcPrefix "J05".
- Q2740966 atcSuffix "AX11".
- Q2740966 casNumber "697761-98-1".
- Q2740966 chEBI "72289".
- Q2740966 fdaUniiCode "4GDQ854U53".
- Q2740966 iupacName "6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid".
- Q2740966 pubchem "5277135".
- Q2740966 thumbnail Elvitegravir_structure.svg?width=300.
- Q2740966 wikiPageWikiLink Q15787.
- Q2740966 wikiPageWikiLink Q1779868.
- Q2740966 wikiPageWikiLink Q204711.
- Q2740966 wikiPageWikiLink Q2528140.
- Q2740966 wikiPageWikiLink Q422618.
- Q2740966 wikiPageWikiLink Q5014970.
- Q2740966 wikiPageWikiLink Q5282001.
- Q2740966 wikiPageWikiLink Q5368263.
- Q2740966 wikiPageWikiLink Q663596.
- Q2740966 wikiPageWikiLink Q7116685.
- Q2740966 wikiPageWikiLink Q7251230.
- Q2740966 wikiPageWikiLink Q8549960.
- Q2740966 wikiPageWikiLink Q8561985.
- Q2740966 wikiPageWikiLink Q8919936.
- Q2740966 wikiPageWikiLink Q898568.
- Q2740966 wikiPageWikiLink Q9052323.
- Q2740966 atcPrefix "J05".
- Q2740966 atcSuffix "AX11".
- Q2740966 casNumber "697761".
- Q2740966 chebi "72289".
- Q2740966 iupacName "6".
- Q2740966 pubchem "5277135".
- Q2740966 unii "4".
- Q2740966 type ChemicalSubstance.
- Q2740966 type Drug.
- Q2740966 type ChemicalObject.
- Q2740966 type Thing.
- Q2740966 type Q8386.
- Q2740966 comment "Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.".
- Q2740966 label "Elvitegravir".
- Q2740966 depiction Elvitegravir_structure.svg.